$Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3$

Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal for immunotherapy of cancer 2015-11, Vol.3 (Suppl 2), p.O8-O8
Hauptverfasser:	Powderly, John, Cote, Gregory, Flaherty, Keith, Szmulewitz, Russell Z, Ribas, Antoni, Weber, Jeffrey, Loo, Deryk, Baughman, Jan, Chen, Francine, Moore, Paul, Bonvini, Ezio, Vasselli, James, Wigginton, Jon, Cohen, Roger, Burris, Howard, Chmielowski, Bartosz
Format:	Artikel
Sprache:	eng
Schlagworte:	Cancer Care and treatment Dose-response relationship (Biochemistry) Drug dosages Immunotherapy Kidney cancer Melanoma Methods Oral Presentation Patient outcomes Patients Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:
ISSN:	2051-1426 2051-1426
DOI:	10.1186/2051-1426-3-S2-O8